Interferon-beta treatment increases human papillomavirus early gene transcription and viral plasmid genome replication by activating interferon regulatory factor (IRF)-1

Carcinogenesis

Volumn 30, Issue 8, 2009, Pages 1336-1344

  Lace, Michael J ^a,b   Anson, James R ^a   Klingelhutz, Aloysius J ^b   Harada, Hisashi ^c   Taniguchi, Tadatsugu ^d   Bossle, Aaron D ^b   Haugen, Thomas H ^a,b   Turek, Lubomir P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; IRF1 PROTEIN, HUMAN; IRF1 PROTEIN, MOUSE; IRF2 PROTEIN, MOUSE; PRIMER DNA;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE ACTIVATION; GENE DUPLICATION; GENE EXPRESSION; GENE FUNCTION; GENE NUMBER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; IMMUNE RESPONSE; KERATINOCYTE; MUTAGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; WART VIRUS; ANIMAL; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECT; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; PROMOTER REGION; VIROLOGY; VIRUS GENOME;

ANIMALS; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTOR-2; INTERFERON-BETA; KERATINOCYTES; MICE; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 69449100234     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp150     Document Type: Article

References (59)

1. Psyrri, A. et al. (2008) Human papillomavirus in cervical and head-and-neck cancer. Nat. Clin. Pract. Oncol., 5, 24-31.
2. Munoz-Fontela, C. et al. (2007) Control of virus infection by tumour suppressors. Carcinogenesis, 28, 1140-1144.
3. Garcia-Sastre, A. et al. (2006) Type 1 interferons and the virus-host relationship: A lesson in detente. Science, 312, 879-882.
4. Kimberlin, D. W. (2004) Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res. 63, 141-151.
5. Szeps, M. et al. (2005) Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alpha interferon treatment. J. Gen. Virol., 86, 1695-1702.
6. Gerein, V. et al. (2005) Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann. Otol. Rhinol. Laryngol., 114, 463-471.
7. Kim, K. Y. et al. (2000) The effects of interferon on the expression of human papillomavirus oncogenes. J. Gen. Virol., 81(Pt 3), 695-700.
8. Tindle, R. W. (2002) Immune evasion in human papillomavirus-associated cervical cancer. Nat. Rev. Cancer, 2, 59-65.
9. Kanodia, S. et al. (2007) Mechanisms used by human papillomaviruses to escape the host immune response. Curr. Cancer Drug Targets, 7, 79-89.
10. Frazer, I. H. et al. (1999) Potential strategies utilised by papillomavirus to evade host immunity. Immunol. Rev., 168, 131-142.
11. Delvenne, P. (2005) Immunologic response to (pre)neoplastic cervical lesions associated with human papillomavirus. Bull Mem. Acad. R. Med. Belg., 160, 287-293.
12. Kobayashi, A. et al. (2008) Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol., 1, 412-420.
13. Alazawi, W. et al. (2002) Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res., 62, 6959-6965.
14. Stanley, M. (2008) Immunobiology of HPV and HPV vaccines. Gynecol. Oncol., 109, S15-S21.
15. Koromilas, A. E. et al. (2001) Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev., 12 157-170.
16. Scott, M. E. et al. (2009) Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int. J. Cancer, 124, 1379-1383.
17. Chang, Y. E. et al. (2000) Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol., 74, 4174-4182.
18. Nees, M. et al. (2001) Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol., 75, 4283-4296.
19. Thomas, J. T. et al. (2001) Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. J. Virol., 75, 7564-7571.
20. Ronco, L. V. et al. (1998) Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev., 12, 2061-2072.
21. Arany, I. et al. (2003) A functional interferon regulatory factor-1 (IRF-1)-binding site in the upstream regulatory region (URR) of human papillomavirus type 16. Virology, 310, 280-286.
22. Antonsson, A. et al. (2006) The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J. Interferon Cytokine Res., 26, 455-461.
23. Um, S. J. et al. (2002) Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett., 179, 205-212.
24. Park, J. S. et al. (2000) Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem., 275, 6764-6769.
25. Cordano, P. et al. (2008) The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. Virology, 377, 408-418.
26. Reich, N. C. (2002) Nuclear/cytoplasmic localization of IRFs in response to viral infection or interferon stimulation. J. Interferon Cytokine Res., 22, 103-109.
27. Taniguchi, T. et al. (2001) IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol., 19, 623-655.
28. Romeo, G. et al. (2002) IRF-1 as a negative regulator of cell proliferation. J. Interferon Cytokine Res., 22, 39-47.
29. Tanaka, N. et al. (1994) Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell, 77, 829-840.
30. Willman, C. L. et al. (1993) Deletion of IRF-1, mapping to chromosome 5q31. 1, in human leukemia and preleukemic myelodysplasia. Science, 259, 968-971.
31. Ida-Hosonuma, M. et al. (2005) The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J. Virol. 79, 4460-4469.
32. Sainz, B. Jr et al. (2004) Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology, 329, 11-17.
33. Herdman, M. T. et al. (2006) Interferon-{beta} treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis, 27, 2341-2353.
34. Pett, M. R. et al. (2006) Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc. Natl Acad. Sci. USA, 103 3822-3827.
35. Rheinwald, J. G. et al. (1975) Serial cultivation of strains of human epidermal keratinocytes: The formation of keratinizing colonies from single cells. Cell, 6, 331-343.
36. Lace, M. J. et al. (2008) The E8-E2 gene product of human papillomavirus type 16 represses early transcription and replication but is dispensable for viral plasmid persistence in keratinocytes. J. Virol., 82, 10841-10853.
37. Sprague, D. L. et al. (2002) Telomerase activation in cervical keratinocytes containing stably replicating human papillomavirus type 16 episomes. Virology, 301, 247-254.
38. Rheinwald, J. G. et al. (1981) Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res., 41, 1657-1663.
39. Hubert, W. G. et al. (1999) DNA replication of human papillomavirus type 31 is modulated by elements of the upstream regulatory region that lie 5′ of the minimal origin. J. Virol., 73, 1835-1845.
40. Dürst, M. et al. (1995) Malignant progression of an HPV16-immortalized human keratinocyte cell line (HPKIA) in vitro. Cancer Genet. Cytogenet., 85, 105-112.
41. Boukamp, P. et al. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106, 761-771.
42. Cripe, T. P. et al. (1990) Transcriptional activation of the human papillomavirus-16 P97 promoter by an 88-nucleotide enhancer containing distinct cell-dependent and AP-1-responsive modules. New Biol., 2, 450-463.
43. Ishiji, T. et al. (1992) Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in human keratinocytes and cervical carcinoma cells. EMBO J., 11, 2271-2281.
44. Jeon, S. et al. (1995) Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis. Proc. Natl Acad. Sci. USA, 92, 1654-1658.
45. Meyers, C. et al. (1992) Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science, 257, 971-973.
46. Harada, H. et al. (1994) Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: Implications for a gene network in the interferon system. Mol. Cell. Biol., 14 1500-1509.
47. Imperiale, M. J. et al. (1985) An enhancer-like element in the adenovirus E2 promoter contains sequences essential for uninduced and E1A-induced transcription. Proc. Natl Acad. Sci. USA, 82, 381-385.
48. Flores, E. R. et al. (1999) Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology, 262, 344-354.
49. Goldsborough, M. D. et al. (1989) Nucleotide sequence of human papillomavirus type 31: A cervical neoplasia-associated virus. Virology, 171, 306-311.
50. Gissmann, L. et al. (1982) Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J. Virol., 44, 393-400.
51. Ushikai, M. et al. (1994) trans activation by the full-length E2 proteins of human papillomavirus type 16 and bovine papillomavirus type 1 in vitro and in vivo: Cooperation with activation domains of cellular transcription factors. J. Virol., 68, 6655-6666.
52. Fujita, T. et al. (1989) Induction of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. Nature 337, 270-272.
53. Harada, H. et al. (1989) Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell, 58, 729-739.
54. Veldman, T. et al. (2003) Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl Acad. Sci. USA 100, 8211-8216.
55. Boeckle, S. et al. (2002) A new cellular factor recognizes E2 binding sites of papillomaviruses which mediate transcriptional repression by E2. Virology, 293, 103-117.
56. Goon, P. et al. (2008) Recurrent respiratory papillomatosis: An overview of current thinking and treatment. Eur. Arch. Otorhinolaryngol., 265, 147-151.
57. Chang, Y. E. et al. (2002) Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J. Virol. 76, 8864-8874.
58. Turek, L. P. et al. (1982) Interferon induces morphologic reversion with elimination of extrachromosomal viral genomes in bovine papillomavirus-transformed mouse cells. Proc. Natl Acad. Sci. USA, 79, 7914-7918.
59. Lace, M. J. et al. (2008) Functional mapping of the human papillomavirus type 16 E1 cistron. J. Virol., 82, 10724-10734.